Literature DB >> 17525748

Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR.

M Ebauer1, M Wachtel, F K Niggli, B W Schäfer.   

Abstract

The chromosomal translocation t(2;13), characteristic for the aggressive childhood cancer alveolar rhabdomyosarcoma (aRMS), generates the chimeric transcription factor PAX3/FKHR with a well known oncogenic role. However, the molecular mechanisms mediating essential pathophysiological functions remain poorly defined. Here, we used comparative expression profiling of PAX3/FKHR silencing in vitro and PAX3/FKHR-specific gene signatures in vivo to identify physiologically important target genes. Hereby, 51 activated genes, both novel and known, were identified. We also found repression of skeletal muscle-specific genes suggesting that PAX3/FKHR blocks further differentiation of aRMS cells. Importantly, TFAP2B was validated as direct target gene mediating the anti-apoptotic function of PAX3/FKHR. Hence, we developed a pathophysiologically relevant transcriptional profile of PAX3/FKHR and identified a critical target gene for aRMS development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525748     DOI: 10.1038/sj.onc.1210525

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Authors:  Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

2.  Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.

Authors:  Lisa E S Crose; Kathleen A Galindo; Julie Grondin Kephart; Candy Chen; Julien Fitamant; Nabeel Bardeesy; Rex C Bentley; Rene L Galindo; Jen-Tsan Ashley Chi; Corinne M Linardic
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

3.  PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.

Authors:  Puspa R Pandey; Bishwanath Chatterjee; Mary E Olanich; Javed Khan; Markku M Miettinen; Stephen M Hewitt; Frederic G Barr
Journal:  J Pathol       Date:  2017-03-01       Impact factor: 7.996

4.  Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.

Authors:  Maria Böhm; Marco Wachtel; Joana G Marques; Natalie Streiff; Dominik Laubscher; Paolo Nanni; Kamel Mamchaoui; Raffaella Santoro; Beat W Schäfer
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

5.  PAX3-FKHR sensitizes human alveolar rhabdomyosarcoma cells to camptothecin-mediated growth inhibition and apoptosis.

Authors:  Fu-Yue Zeng; Jimmy Cui; Lingling Liu; Taosheng Chen
Journal:  Cancer Lett       Date:  2009-05-12       Impact factor: 8.679

Review 6.  Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease.

Authors:  Jennifer D Kubic; Kacey P Young; Rebecca S Plummer; Anton E Ludvik; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2008-12       Impact factor: 4.693

7.  Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Authors:  Kaiji Hu; Cathy Lee; Dexin Qiu; Abbas Fotovati; Alastair Davies; Samah Abu-Ali; Daniel Wai; Elizabeth R Lawlor; Timothy J Triche; Catherine J Pallen; Sandra E Dunn
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

8.  High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts.

Authors:  Shujuan J Xia; Dara D Holder; Bruce R Pawel; Chune Zhang; Frederic G Barr
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

9.  Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.

Authors:  Mathivanan Jothi; Munmun Mal; Charles Keller; Asoke K Mal
Journal:  Mol Cancer Ther       Date:  2013-10-09       Impact factor: 6.261

10.  Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes.

Authors:  Kaisa Thorell; Annika Bergman; Helena Carén; Staffan Nilsson; Per Kogner; Tommy Martinsson; Frida Abel
Journal:  BMC Med Genomics       Date:  2009-08-17       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.